CL2018001621A1 - Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) - Google Patents
Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)Info
- Publication number
- CL2018001621A1 CL2018001621A1 CL2018001621A CL2018001621A CL2018001621A1 CL 2018001621 A1 CL2018001621 A1 CL 2018001621A1 CL 2018001621 A CL2018001621 A CL 2018001621A CL 2018001621 A CL2018001621 A CL 2018001621A CL 2018001621 A1 CL2018001621 A1 CL 2018001621A1
- Authority
- CL
- Chile
- Prior art keywords
- apj
- heteroarylhydroxypyrimidinones
- apeline
- receptor agonists
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE LA FÓRMULA (I), EN DONDE TODAS LAS VARIABLES SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA, Y COMPOSICIONES QUE COMPRENDEN CUALQUIERA DE TALES COMPUESTOS NOVEDOSOS. ESTOS COMPUESTOS SON AGONISTAS DE APJ QUE SE PUEDEN USAR COMO MEDICAMENTOS, EN PARTICULAR PARA EL TRATAMIENTO DE TRASTORNOS CARDIOVASCULARES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267997P | 2015-12-16 | 2015-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018001621A1 true CL2018001621A1 (es) | 2018-08-03 |
Family
ID=57708840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001621A CL2018001621A1 (es) | 2015-12-16 | 2018-06-15 | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) |
Country Status (21)
Country | Link |
---|---|
US (1) | US10669261B2 (es) |
EP (1) | EP3390400B1 (es) |
JP (1) | JP6948322B2 (es) |
KR (1) | KR20180095577A (es) |
CN (1) | CN108602813B (es) |
AR (1) | AR107061A1 (es) |
AU (1) | AU2016372048B2 (es) |
BR (1) | BR112018012112A2 (es) |
CA (1) | CA3008630A1 (es) |
CL (1) | CL2018001621A1 (es) |
CO (1) | CO2018007221A2 (es) |
EA (1) | EA036736B1 (es) |
ES (1) | ES2854733T3 (es) |
HK (1) | HK1255163A1 (es) |
IL (1) | IL259947B (es) |
MX (1) | MX2018007155A (es) |
PE (1) | PE20181487A1 (es) |
SG (1) | SG11201804674UA (es) |
TW (1) | TW201725203A (es) |
UY (1) | UY37026A (es) |
WO (1) | WO2017106396A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2739526T3 (es) | 2015-06-03 | 2020-01-31 | Bristol Myers Squibb Co | Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares |
JP6837482B2 (ja) | 2015-10-14 | 2021-03-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド |
US11390616B2 (en) | 2015-12-04 | 2022-07-19 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
EP3782994A1 (en) | 2015-12-16 | 2021-02-24 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
MA43761A (fr) | 2016-03-24 | 2021-05-05 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj |
EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
US10889565B2 (en) | 2016-06-14 | 2021-01-12 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists |
CN109311821B (zh) * | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
JP7037558B2 (ja) | 2016-10-14 | 2022-03-16 | ブリストル-マイヤーズ スクイブ カンパニー | 3-スルホニル-5-アミノピリジン-2,4-ジオール apjアゴニスト |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
US6174998B1 (en) | 1996-03-12 | 2001-01-16 | Roche Diagnostics Gmbh | C-nucleoside derivatives and their use in the detection of nucleic acids |
JPH08311041A (ja) | 1995-03-16 | 1996-11-26 | Takeda Chem Ind Ltd | 複素環化合物およびその剤 |
CZ298812B6 (cs) | 1996-07-01 | 2008-02-13 | Dr. Reddy's Laboratories Limited | Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí |
US6369067B1 (en) | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
BRPI0108396B1 (pt) * | 2000-02-16 | 2015-05-19 | Smithkline Beecham Plc | Derivados de pirimidina-4-ona como inibidores de ldl-pla2 |
EP1301490A2 (en) | 2000-07-18 | 2003-04-16 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
WO2002081454A1 (en) | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
PL373412A1 (en) | 2002-05-09 | 2005-08-22 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods of their use for treating cellular proliferative diseases |
JP2005530806A (ja) | 2002-05-23 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | 有糸***キネシン阻害薬 |
US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
WO2004094408A1 (en) | 2003-04-23 | 2004-11-04 | Pharmacia & Upjohn Company Llc | Substituted pyrimidinones and pyrimidinthiones as crf antagonists |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
WO2005041888A2 (en) | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
US7625912B2 (en) | 2003-12-19 | 2009-12-01 | Merck & Co. Inc | Mitotic kinesin inhibitors |
JP4517349B2 (ja) | 2004-07-28 | 2010-08-04 | 宇部興産株式会社 | ピリミジン−4−オン化合物の製造方法 |
DE102005025315A1 (de) | 2005-06-02 | 2006-12-14 | Merck Patent Gmbh | Ionische Flüssigkeiten mit niedriger Viskosität |
WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | c-Met의 억제제 및 이의 용도 |
WO2007124397A2 (en) | 2006-04-21 | 2007-11-01 | Trustees Of Boston University | Ionic viscoelastics and viscoelastic salts |
ES2527722T3 (es) | 2006-10-10 | 2015-01-28 | Proionic Gmbh & Co Kg | Método para reaccionar 2-carboxilatos 1,3-heteroaromáticos con agua |
WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
WO2009152902A2 (en) | 2008-05-28 | 2009-12-23 | Merck Patent Gmbh, | Ionic liquids |
DE102008031480A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Salze enthaltend ein Pyrimidincarbonsäure-Derivat |
WO2010072696A2 (de) | 2008-12-22 | 2010-07-01 | Basf Se | Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern |
AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
WO2012020742A1 (ja) | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
TWI567084B (zh) | 2011-05-31 | 2017-01-21 | 麥克專利有限公司 | 含有氫-三氰-硼酸根陰離子之化合物 |
KR20140039242A (ko) | 2011-05-31 | 2014-04-01 | 메르크 파텐트 게엠베하 | 전해질 제형 |
CN102903954B (zh) | 2011-07-25 | 2015-06-03 | 微宏动力***(湖州)有限公司 | 含有离子液体电解质的锂离子二次电池 |
DE102012006896A1 (de) | 2012-04-05 | 2013-10-10 | Merck Patent Gmbh | Silikate mit organischen Kationen |
US9957247B2 (en) | 2012-06-07 | 2018-05-01 | Georgia State University Research Foundation, Inc. | SecA inhibitors and methods of making and using thereof |
US9156796B2 (en) * | 2012-09-21 | 2015-10-13 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators |
WO2014056844A1 (en) | 2012-10-10 | 2014-04-17 | Basf Se | Ionic liquids based on oxalic acid mono esters |
DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
EP3251674A3 (en) | 2012-11-16 | 2018-02-21 | BioCryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
DE102013016324A1 (de) | 2013-10-04 | 2015-04-09 | Merck Patent Gmbh | Perfluoralkylfluor- oder Perfluoralkylchlorgermanate |
CA2930343C (en) | 2013-11-29 | 2021-06-08 | Proionic Gmbh | Method for curing an adhesive using microwave irradiation |
KR101550846B1 (ko) | 2014-01-29 | 2015-09-07 | 한국과학기술연구원 | 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도 |
KR101531023B1 (ko) | 2014-05-27 | 2015-06-23 | 한국과학기술연구원 | 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유 |
WO2015184011A2 (en) * | 2014-05-28 | 2015-12-03 | Sanford-Burnham Medical Research Institute | Agonists of the apelin receptor and methods of use thereof |
CA2949559C (en) * | 2014-06-06 | 2023-08-29 | Research Triangle Institute | Apelin receptor (apj) agonists and uses thereof |
WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
ES2739526T3 (es) * | 2015-06-03 | 2020-01-31 | Bristol Myers Squibb Co | Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares |
JP6837482B2 (ja) | 2015-10-14 | 2021-03-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Apjアゴニストとしての2,4−ジヒドロキシ−ニコチンアミド |
US11390616B2 (en) | 2015-12-04 | 2022-07-19 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
MA43761A (fr) | 2016-03-24 | 2021-05-05 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj |
CN109311821B (zh) | 2016-06-14 | 2022-10-14 | 百时美施贵宝公司 | 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮 |
US10889565B2 (en) | 2016-06-14 | 2021-01-12 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists |
JP7037558B2 (ja) | 2016-10-14 | 2022-03-16 | ブリストル-マイヤーズ スクイブ カンパニー | 3-スルホニル-5-アミノピリジン-2,4-ジオール apjアゴニスト |
-
2016
- 2016-12-15 EP EP16820507.8A patent/EP3390400B1/en active Active
- 2016-12-15 CN CN201680081704.3A patent/CN108602813B/zh active Active
- 2016-12-15 AR ARP160103867A patent/AR107061A1/es unknown
- 2016-12-15 ES ES16820507T patent/ES2854733T3/es active Active
- 2016-12-15 TW TW105141572A patent/TW201725203A/zh unknown
- 2016-12-15 SG SG11201804674UA patent/SG11201804674UA/en unknown
- 2016-12-15 UY UY0001037026A patent/UY37026A/es unknown
- 2016-12-15 AU AU2016372048A patent/AU2016372048B2/en not_active Ceased
- 2016-12-15 KR KR1020187019799A patent/KR20180095577A/ko not_active Application Discontinuation
- 2016-12-15 JP JP2018531333A patent/JP6948322B2/ja active Active
- 2016-12-15 MX MX2018007155A patent/MX2018007155A/es unknown
- 2016-12-15 WO PCT/US2016/066750 patent/WO2017106396A1/en active Application Filing
- 2016-12-15 US US16/061,365 patent/US10669261B2/en active Active
- 2016-12-15 BR BR112018012112-6A patent/BR112018012112A2/pt not_active Application Discontinuation
- 2016-12-15 PE PE2018001129A patent/PE20181487A1/es unknown
- 2016-12-15 CA CA3008630A patent/CA3008630A1/en not_active Abandoned
- 2016-12-15 EA EA201891336A patent/EA036736B1/ru not_active IP Right Cessation
-
2018
- 2018-06-11 IL IL259947A patent/IL259947B/en active IP Right Grant
- 2018-06-15 CL CL2018001621A patent/CL2018001621A1/es unknown
- 2018-07-11 CO CONC2018/0007221A patent/CO2018007221A2/es unknown
- 2018-11-08 HK HK18114280.0A patent/HK1255163A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016372048B2 (en) | 2021-02-04 |
EA036736B1 (ru) | 2020-12-14 |
PE20181487A1 (es) | 2018-09-18 |
AR107061A1 (es) | 2018-03-14 |
UY37026A (es) | 2017-06-30 |
HK1255163A1 (zh) | 2019-08-09 |
WO2017106396A1 (en) | 2017-06-22 |
CN108602813A (zh) | 2018-09-28 |
EP3390400A1 (en) | 2018-10-24 |
MX2018007155A (es) | 2018-08-15 |
EA201891336A1 (ru) | 2019-01-31 |
SG11201804674UA (en) | 2018-06-28 |
CN108602813B (zh) | 2021-10-29 |
TW201725203A (zh) | 2017-07-16 |
JP6948322B2 (ja) | 2021-10-13 |
US20180362508A1 (en) | 2018-12-20 |
JP2018538304A (ja) | 2018-12-27 |
ES2854733T3 (es) | 2021-09-22 |
US10669261B2 (en) | 2020-06-02 |
AU2016372048A1 (en) | 2018-08-02 |
IL259947B (en) | 2020-10-29 |
EP3390400B1 (en) | 2021-01-20 |
CO2018007221A2 (es) | 2018-07-19 |
KR20180095577A (ko) | 2018-08-27 |
IL259947A (en) | 2018-07-31 |
BR112018012112A2 (pt) | 2018-12-04 |
CA3008630A1 (en) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001621A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
CL2018001478A1 (es) | Agonistas del receptor de apelina y métodos de uso | |
CO2018004968A2 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
CL2017003055A1 (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares. | |
CL2018002671A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj) | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
ECSP18060342A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
CL2018001230A1 (es) | Tratamiento de osteoartritis | |
CL2018000150A1 (es) | Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508) | |
UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
NI201600164A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CR20180058A (es) | Nuevos derivados de fenoximetilo | |
ECSP17064695A (es) | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 | |
UY37018A (es) | Inhibidores bicíclicos de pad4 | |
GT201800020A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
CO2017004074A2 (es) | Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
DOP2018000219A (es) | Anticuerpos anti-factor bb del complemento y usos de estos | |
UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
CU20200038A7 (es) | Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3 | |
CU24618B1 (es) | 1-arilnaftiridin-3-carboxamidas 7-sustituidas como moduladores del receptor m2 muscarinérgico | |
CR20170498A (es) | 2-tiopirimidinonas | |
UY36086A (es) | Compuestos de quinoxalina y usos de los mismos |